Press

Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder

Apr 19 • 4 min read

Wesana Health Holdings Inc. (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms, is pleased to announce that following the completion of a successful Pre-IND meeting with the United States Food and Drug Administration, the Company is exploring the opportunity to expand its…

Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19

Apr 18 • 3 min read

Revive Therapeutics Ltd. (OTCQB: RVVTF | CSE: RVV | FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced the publication of a scientific article evaluating the impact of medication, including Bucillamine, on antibody response to SARS-CoV-2 mRNA vaccines in Japanese patients with…

NeonMind Announces Plan to Launch 10 Clinics for Innovative Treatments as Mental Health Crisis Grows

Apr 15 • 4 min read

NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF), an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders, announced plans to launch 10 specialty mental health clinics over the next 3 years through alliances with SRx Health Solutions and BioScript Solutions, leading…

Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway

Apr 14 • 4 min read

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a biotechnology company, researching, developing, and delivering revolutionary therapeutics to treat addiction, today is providing shareholders with a business update on its three fully-operational ketamine-assisted therapy clinics, two in the UK and one in Norway. Awakn’s clinics team consists of some of the world’s leading…

Delic Labs Receives Health Canada 56 Exemption to Conduct Research on MDMA, LSD and Other Psychedelic Compounds

Apr 13 • 4 min read

Delic Holdings Corp (CSE: DELC | OTCQB: DELCF | FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that its subsidiary, Delic Labs, received a Health Canada 56 Research Exemption that will allow scientists to conduct research and perform tests on a number of compounds outside of psychedelic mushrooms,…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435